Search Results

BioSkryb Genomics announced a partnership with Research Instruments Pte Ltd, a premier distributor for genomic and life science research products in Southeast Asia, to distribute BioSkryb’s ResolveDNA® and ResolveOME™ single cell amplification tools throughout Singapore and Southeast Asia.

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems, and Radiant Digital PTE Ltd. a provider of digital transformation delivery services to commercial and government clients, have partnered to facilitate the digital transformation of life sciences companies in Singapore.

CellResearch Corporation, a Singapore-based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy.

Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has entered into a distribution agreement with BIOASIA PTE LTD (“Bioasia”), a medical diagnostics distributor located in Singapore.

SCG Cell Therapy Pte Ltd announced that U.S. Food and Drug Administration has approved the Investigational New Drug application to initiate Phase 1/2 clinical trial for SCG142, a novel next-generation human papillomavirus E7-specific T-cell receptor-engineered T cell therapy for patients with HPV-associated solid tumors.

PharmaGend Global Medical Services Pte. Ltd., jointly invested by China Medical System Holdings Limited, through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., and its non-wholly owned subsidiary Rxilient Health Pte. Ltd., with Pharmaron International Limited and Healthy Goal Limited, has entered into a lease agreement for the building and property located in Tuas, Singapore and completed the purchase of certain production machines and equipment from Strides Pharma Global Pte.

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000.

Helsinn Group and Juniper Biologics Pte Ltd announced the signing of an exclusive distribution license and supply agreement to register, distribute, promote, market and sell LEDAGA® in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma in adults.